Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer

Detalles Bibliográficos
Autores principales: Zhou, Yunxiang, Wang, Xiaojia, Chen, Yiding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Highlights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318489/
https://www.ncbi.nlm.nih.gov/pubmed/37409110
http://dx.doi.org/10.1002/mco2.322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318489/
https://www.ncbi.nlm.nih.gov/pubmed/37409110
http://dx.doi.org/10.1002/mco2.322

Ejemplares similares